{"id":17681,"date":"2024-12-12T14:53:05","date_gmt":"2024-12-12T06:53:05","guid":{"rendered":"https:\/\/flcube.com\/?p=17681"},"modified":"2024-12-12T14:53:07","modified_gmt":"2024-12-12T06:53:07","slug":"angitia-biopharmaceuticals-secures-usd-120-million-in-series-c-financing-for-musculoskeletal-treatments","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=17681","title":{"rendered":"Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments"},"content":{"rendered":"\n<p>Angitia Biopharmaceuticals, a provider of solutions for musculoskeletal diseases operating out of Guangzhou, China, and California, the US, has announced the successful closing of a USD 120 million Series C financing round. The funding was led by Bain Capital Life Sciences and included contributions from Janus Henderson and existing investors such as OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital, and Elikon Venture. The proceeds from this financing will support Angitia\u2019s robust pipeline of novel and differentiated treatments for serious musculoskeletal diseases.<\/p>\n\n\n\n<p><strong>Advancing Innovative Treatments for Musculoskeletal Conditions<\/strong><br>Angitia is currently advancing two bispecific antibodies, AGA2118 and AGA2115, which target sclerostin and DKK1, respectively. These candidates are being developed for the treatment of osteoporosis and osteogenesis imperfecta (OI). Additionally, the company is working on AGA111, a biologic designed to promote spinal fusion in patients suffering from degenerative disc disease. This innovative pipeline reflects Angitia&#8217;s commitment to addressing significant unmet medical needs in the musculoskeletal disease space.<\/p>\n\n\n\n<p><strong>Strategic Partnerships and Future Growth<\/strong><br>The successful Series C financing not only enhances Angitia&#8217;s financial position but also underscores the confidence of prominent investors in the company&#8217;s vision and potential. With the backing of leading investment firms, Angitia is well-positioned to accelerate the clinical development of its promising therapies and make a meaningful impact in the treatment of musculoskeletal diseases.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Angitia Biopharmaceuticals, a provider of solutions for musculoskeletal diseases operating out of Guangzhou, China, and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":17683,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1454,20],"class_list":["post-17681","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-angitia-biopharmaceuticals","tag-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Angitia Biopharmaceuticals, a provider of solutions for musculoskeletal diseases operating out of Guangzhou, China, and California, the US, has announced the successful closing of a USD 120 million Series C financing round. The funding was led by Bain Capital Life Sciences and included contributions from Janus Henderson and existing investors such as OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital, and Elikon Venture. The proceeds from this financing will support Angitia\u2019s robust pipeline of novel and differentiated treatments for serious musculoskeletal diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=17681\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=17681\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-12T06:53:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-12T06:53:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1212.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"704\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17681#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17681\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments\",\"datePublished\":\"2024-12-12T06:53:05+00:00\",\"dateModified\":\"2024-12-12T06:53:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17681\"},\"wordCount\":235,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17681#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1212.png\",\"keywords\":[\"Angitia Biopharmaceuticals\",\"Finance\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17681#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17681\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=17681\",\"name\":\"Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17681#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17681#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1212.png\",\"datePublished\":\"2024-12-12T06:53:05+00:00\",\"dateModified\":\"2024-12-12T06:53:07+00:00\",\"description\":\"Angitia Biopharmaceuticals, a provider of solutions for musculoskeletal diseases operating out of Guangzhou, China, and California, the US, has announced the successful closing of a USD 120 million Series C financing round. The funding was led by Bain Capital Life Sciences and included contributions from Janus Henderson and existing investors such as OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital, and Elikon Venture. The proceeds from this financing will support Angitia\u2019s robust pipeline of novel and differentiated treatments for serious musculoskeletal diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17681#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17681\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17681#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1212.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1212.png\",\"width\":1080,\"height\":704,\"caption\":\"Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17681#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments - Insight, China&#039;s Pharmaceutical Industry","description":"Angitia Biopharmaceuticals, a provider of solutions for musculoskeletal diseases operating out of Guangzhou, China, and California, the US, has announced the successful closing of a USD 120 million Series C financing round. The funding was led by Bain Capital Life Sciences and included contributions from Janus Henderson and existing investors such as OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital, and Elikon Venture. The proceeds from this financing will support Angitia\u2019s robust pipeline of novel and differentiated treatments for serious musculoskeletal diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=17681","og_locale":"en_US","og_type":"article","og_title":"Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=17681","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-12T06:53:05+00:00","article_modified_time":"2024-12-12T06:53:07+00:00","og_image":[{"width":1080,"height":704,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1212.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=17681#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=17681"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments","datePublished":"2024-12-12T06:53:05+00:00","dateModified":"2024-12-12T06:53:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=17681"},"wordCount":235,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=17681#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1212.png","keywords":["Angitia Biopharmaceuticals","Finance"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=17681#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=17681","url":"https:\/\/flcube.com\/?p=17681","name":"Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=17681#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=17681#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1212.png","datePublished":"2024-12-12T06:53:05+00:00","dateModified":"2024-12-12T06:53:07+00:00","description":"Angitia Biopharmaceuticals, a provider of solutions for musculoskeletal diseases operating out of Guangzhou, China, and California, the US, has announced the successful closing of a USD 120 million Series C financing round. The funding was led by Bain Capital Life Sciences and included contributions from Janus Henderson and existing investors such as OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital, and Elikon Venture. The proceeds from this financing will support Angitia\u2019s robust pipeline of novel and differentiated treatments for serious musculoskeletal diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=17681#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=17681"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=17681#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1212.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1212.png","width":1080,"height":704,"caption":"Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=17681#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1212.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17681"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17681\/revisions"}],"predecessor-version":[{"id":17684,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17681\/revisions\/17684"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/17683"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}